Shantha Biotechnics Revenue and Competitors
Estimated Revenue & Valuation
- Shantha Biotechnics's estimated annual revenue is currently $4.6M per year.
- Shantha Biotechnics's estimated revenue per employee is $77,500
Employee Data
- Shantha Biotechnics has 59 Employees.
- Shantha Biotechnics grew their employee count by 4% last year.
Shantha Biotechnics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12M | 155 | -4% | N/A | N/A |
#2 | $17.3M | 223 | 18% | N/A | N/A |
#3 | $11.1M | 143 | 34% | N/A | N/A |
#4 | $8.2M | 106 | 8% | N/A | N/A |
#5 | $9.5M | 123 | 10% | N/A | N/A |
#6 | $21.2M | 273 | 8% | N/A | N/A |
#7 | $12M | 155 | 8% | N/A | N/A |
#8 | $18.9M | 244 | 5% | N/A | N/A |
#9 | $12.5M | 161 | 9% | N/A | N/A |
#10 | $20.5M | 264 | 8% | N/A | N/A |
What Is Shantha Biotechnics?
Shantha Biotechnics - India is a biotechnology company based out of Fateh Maidan Road Basheerbagh, Hyderabad, Andhra Pradesh, India.
keywords:N/A
N/A
Total Funding
59
Number of Employees
$4.6M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Shantha Biotechnics News
2022-04-17 - Global Tetanus Vaccine Market 2022 Major Drivers ...
Panera; Shantha Biotechnics Ltd. The report divides the current market into type: Diphtheria and tetanus (DT) vaccines; Diphtheria, tetanus, and...
2022-04-13 - India's Worst Disappointing Public Sector Covid-19 Vaccine ...
Recently, Bharat Biotech collaborated with the Indian Council of ... Shantha Biotechnics developed the country's first r-DNA Hepatitis B...
2022-03-22 - Covaxin, First Made-in-India Covid vaccine, Makers Get Padma Bhushan: Know
Bharat Biotech's Journey
Covaxin maker Bharat Biotech International CMD Krishna Ella, ... 25 cents less than its closest competitor produced by Shantha Biotechnics.
Other Companies in Hyderabad
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.8M | 59 | 64% | N/A |
#2 | $3.8M | 59 | N/A | N/A |
#3 | $2.7M | 59 | 5% | N/A |
#4 | $3.8M | 59 | 23% | N/A |
#5 | $7.3M | 60 | 9% | N/A |